case_images: PMC11153656_01
case_images: Skin toxicity in the patient showing severe paronychia in both feet.
case_images: fonc-14-1381354-g001.jpg
case_images: PMC11153656_01_fonc-14-1381354-g001.jpg
case_images: f1
case_images: During the following 3 years of treatment, with a partial response in the follow-up MRI that was done 6 months after starting treatment, he developed grade 3 skin dermatitis, folliculitis, acneiform lesions, and paronychia (Figure 1), which progressively impaired the patient's quality of life.
case_images: Contrast material-enhanced T1-weighted MR image shows reduction of the solid part of the main tumor (red arrows) as well as the intraventricular enhancing masses (green arrows). (A) Pre-treatment with trametinib; (B) before reducing trametinib dose; (C) end of treatment.
case_images: fonc-14-1381354-g002.jpg
case_images: PMC11153656_01_fonc-14-1381354-g002.jpg
case_images: f2
case_images: Despite this dose reduction, trametinib continued to reduce the size of the tumor in the 3-monthly MRIs that followed the dose reduction (Figure 2), maintaining a partial response even at this reduced dose.
case_images: Timeline describing the treatment of the patient.
case_images: fonc-14-1381354-g003.jpg
case_images: PMC11153656_01_fonc-14-1381354-g003.jpg
case_images: f3
case_images: So far, the patient has not developed any signs of tumor re-growth and continues to be under close follow-up at our institution (Figure 3).